LL-37

Research

LL-37 (Cathelicidin Antimicrobial Peptide)

Aliases
hCAP-18 fragment, Cathelicidin
Administration
Topical (research), Subcutaneous injection (research)

Timing

A general projection of what people report noticing over time, based on the known mechanism and reported use patterns. It is not a guarantee and individual experience varies considerably.

  1. 1

    1–2 Weeks

    For topical or wound-related use, some users report visibly faster healing within the first days to weeks.

  2. 2

    3–4 Weeks

    Continued use is commonly associated with reduced signs of local infection or irritation.

  3. 3

    5–7 Weeks

    Wound-related improvements, where present, tend to continue steadily through this period.

  4. 4

    8–10 Weeks

    Most acute, localized use cases resolve or plateau by this stage.

  5. 5

    11–15 Weeks

    Ongoing use beyond this point is less common outside of chronic wound research contexts.

  6. 6

    16–20 Weeks

    Long-term felt effects have not been well characterized in available research.

  7. 7

    21–24 Weeks

    This duration exceeds most typical use cases studied to date.

⚠️ Research context only. This is not medical advice and results are not guaranteed.